PDCD1 and melanoma: Anti PD-1 chimeric antibody has been developed by a research group which reported reduction of tumor burden, objective partial response in 26% of the treated dogs with a Stage IV oral malignant melanoma, and a trend of increase of survival times, with maintained complete regression for more than 1 year in 2 cases (127, 138).